Correlation between gene mutation status and selected clinical features
Kidney Renal Papillary Cell Carcinoma (Primary solid tumor)
23 May 2013  |  analyses__2013_05_23
Maintainer Information
Citation Information
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Correlation between gene mutation status and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1D21VNQ
Overview
Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 4 genes and 8 clinical features across 101 patients, one significant finding detected with Q value < 0.25.

  • IL32 mutation correlated to 'Time to Death'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between mutation status of 4 genes and 8 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, one significant finding detected.

Clinical
Features
Time
to
Death
AGE GENDER KARNOFSKY
PERFORMANCE
SCORE
DISTANT
METASTASIS
LYMPH
NODE
METASTASIS
TUMOR
STAGECODE
NEOPLASM
DISEASESTAGE
nMutated (%) nWild-Type logrank test t-test Fisher's exact test t-test Fisher's exact test Fisher's exact test t-test Fisher's exact test
IL32 4 (4%) 97 9.44e-15
(2.26e-13)
0.366
(1.00)
0.3
(1.00)
0.217
(1.00)
0.62
(1.00)
0.667
(1.00)
CDC27 4 (4%) 97 0.598
(1.00)
0.78
(1.00)
0.595
(1.00)
0.13
(1.00)
0.153
(1.00)
0.345
(1.00)
NF2 7 (7%) 94 0.598
(1.00)
0.3
(1.00)
1
(1.00)
0.0347
(0.798)
0.075
(1.00)
0.162
(1.00)
SFRS2IP 5 (5%) 96 0.226
(1.00)
0.121
(1.00)
0.661
(1.00)
0.082
(1.00)
0.385
(1.00)
0.316
(1.00)
'IL32 MUTATION STATUS' versus 'Time to Death'

P value = 9.44e-15 (logrank test), Q value = 2.3e-13

Table S1.  Gene #1: 'IL32 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 94 14 0.0 - 182.7 (13.9)
IL32 MUTATED 4 1 3.6 - 7.9 (4.8)
IL32 WILD-TYPE 90 13 0.0 - 182.7 (14.6)

Figure S1.  Get High-res Image Gene #1: 'IL32 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

Methods & Data
Input
  • Mutation data file = KIRP-TP.mutsig.cluster.txt

  • Clinical data file = KIRP-TP.clin.merged.picked.txt

  • Number of patients = 101

  • Number of significantly mutated genes = 4

  • Number of selected clinical features = 8

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)